(Q44414554)

English

Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial

scientific article published in September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

object named as

Janet E Pope

1

0 references

2

object named as

Boulos Haraoui

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

Emmanouil Rampakakis

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Eliofotisti Psaradellis

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Carter Thorne

5

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

John S Sampalis

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Optimization of Adalimumab Trial Investigators

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Arthritis Care and Research

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1401-1409

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

The Work Limitations Questionnaire.

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1002%2FACR.22010

21 January 2018

Identifiers

10.1002/ACR.22010

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44414554&oldid=2022428549"